Company sells 833,332 shares, two series of warrants to Sabby
By Marisa Wong
Morgantown, W.Va., May 19 – Oncobiologics, Inc. raised $5 million from a private placement of common stock arranged on May 11 and completed on May 18, according to an 8-K filing with the Securities and Exchange Commission.
The company issued to Sabby Healthcare Master Fund Ltd. 833,332 shares of common stock, along with 416,666 of series A warrants and 416,666 of series B warrants.
The shares were sold at $6.00 each, which is the price under the company’s concurrent initial public offering of units. The company priced its $35 million IPO on May 12.
Each series A warrant entitles the holder to purchase one common share at an initial exercise price of $6.60 per share and will expire on Feb. 18, 2017. Each series B warrant entitles the holder to purchase one common share at an initial exercise price of $8.50 per share and will expire on May 18, 2018.
Oncobiologics is a biopharmaceutical company is based in Cranbury, N.J.
Issuer: | Oncobiologics, Inc.
|
Issue: | Common stock, warrants
|
Amount: | $5 million
|
Shares: | 833,332
|
Price: | $6.00
|
Warrants: | 416,666 of series A warrants and 416,666 of series B warrants
|
Warrant expiration: | Feb. 18, 2017 for series A, May 18, 2018 for series B
|
Warrant strike price: | $6.60 for series A, $8.50 for series B
|
Investor: | Sabby Healthcare Master Fund Ltd.
|
Pricing date: | May 11
|
Settlement date: | May 18
|
Stock symbol: | Nasdaq: ONSIU
|
Stock price: | $5.11 at close May 18
|
Market capitalization: | $115.38 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.